Walter Investment Management Corp. (WAC) Forms $0.84 Double Bottom; Cancer Genetics (CGIX) Sentiment Is 0.57

Walter Investment Management Corp. (WAC) formed double bottom with $0.78 target or 7.00% below today’s $0.84 share price. Walter Investment Management Corp. (WAC) has $31.50 million valuation. The stock increased 9.10% or $0.0703 during the last trading session, reaching $0.8428. About 1.46 million shares traded or 64.50% up from the average. Walter Investment Management Corp. (NYSE:WAC) has declined 63.57% since January 2, 2017 and is downtrending. It has underperformed by 80.27% the S&P500.

Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker tests and services in the United States, India, and China. The company has market cap of $44.87 million. The Company’s tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. The companyÂ’s clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management.

The stock decreased 2.63% or $0.05 during the last trading session, reaching $1.85. About 593,054 shares traded or 174.73% up from the average. Cancer Genetics, Inc. (CGIX) has risen 81.82% since January 2, 2017 and is uptrending. It has outperformed by 65.12% the S&P500.

Perkins Capital Management Inc holds 2.28% of its portfolio in Cancer Genetics, Inc. for 806,700 shares. Thompson Davis & Co. Inc. owns 46,975 shares or 0.22% of their US portfolio. Moreover, Diker Management Llc has 0.07% invested in the company for 67,055 shares. The Massachusetts-based Granahan Investment Management Inc Ma has invested 0.05% in the stock. Hrt Financial Llc, a New York-based fund reported 15,301 shares.

Analysts await Cancer Genetics, Inc. (NASDAQ:CGIX) to report earnings on March, 22. They expect $-0.10 EPS, up 33.33% or $0.05 from last year’s $-0.15 per share. After $-0.16 actual EPS reported by Cancer Genetics, Inc. for the previous quarter, Wall Street now forecasts -37.50% EPS growth.

Since January 1, 0001, it had 1 buy, and 0 insider sales for $24,339 activity.